Biopharmaceutical company developing seralutinib for the treatment of pulmonary arterial hypertension (PAH).
- Year invested 2022
- Investment Stage Public/PIPES
- Sectors
- Investment Status Current
- Associated Team
- Website gossamerbio.com
- Company Status IPO/Acquired (NASDAQ: GOSS)